Xin Lang Cai Jing·2025-12-02 12:05Core Viewpoint - Eli Lilly has once again reduced the price of its obesity drug Zepbound, intensifying the price competition among GLP-1 medications [1] Pricing Changes - The new prices for Zepbound, applicable for purchases through LillyDirect, are as follows: - 2.5 mg: $299 (previously $349) - 5 mg: $399 (previously $499) - 7.5 mg: $449 (previously $499) - 10 mg: $449 (previously $499) - 12.5 mg: $449 (previously $499) - 15 mg: $449 (previously $499) [2][5][7] Competitive Landscape - This price reduction follows Novo Nordisk's announcement on November 17 regarding self-pay options for Wegovy and Ozempic, with monthly costs capped at $199 until March 31, 2026 [2][3] - Analysts from BMO Capital Markets noted that despite the price cut for Zepbound, it remains higher than Novo Nordisk's self-pay Wegovy [2][5] Government Agreements - Eli Lilly and Novo Nordisk have reached agreements with the U.S. federal government to provide discounts on GLP-1 drugs through Medicare and the upcoming TrumpRx direct sales platform [3][6] - Under this agreement, the prices for Novo Nordisk's Ozempic and Wegovy will drop significantly, while Zepbound and orfoglipron will be offered at an average price of $346 [3][6]